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Abstract: AIMS Cardiac resynchronization therapy (CRT) has become an important therapy in patients
with heart failure with reduced left ventricular ejection fraction (LVEF). The effect of diabetes on long-
term outcome in these patients is controversial. We assessed the effect of diabetes on long-term outcome
in CRT patients and investigated the role of diabetes in ischaemic and non-ischaemic cardiomyopa-
thy. METHODS AND RESULTS All patients undergoing CRT implantation at our institution between
November 2000 and January 2015 were enrolled. The study endpoints were (i) a composite of ventricular
assist device (VAD) implantation, heart transplantation, or all-cause mortality; and (ii) reverse remod-
elling (improvement of LVEF ฀ 10% or reduction of left ventricular end-systolic volume ฀ 15%). Median
follow-up of the 418 patients (age 64.6 ± 11.6 years, 22.5% female, 25.1% diabetes) was 4.8 years [inter-
quartile range: 2.8;7.4]. Diabetic patients had an increased risk to reach the composite endpoint [adjusted
hazard ratio (aHR) 1.48 [95% CI 1.12-2.16], P = 0.041]. Other factors associated with an increased risk to
reach the composite endpoint were a lower body mass index or baseline LVEF (aHR 0.95 [0.91; 0.98] and
0.97 [0.95; 0.99], P < 0.01 each), and a higher New York Heart Association functional class or creatinine
level (aHR 2.14 [1.38; 3.30] and 1.04 [1.01; 1.05], P < 0.05 each). Early response to CRT, defined as
LVEF improvement ฀ 10%, was associated with a lower risk to reach the composite endpoint (aHR 0.60
[0.40; 0.89], P = 0.011). Reverse remodelling did not differ between diabetic and non-diabetic patients
with respect to LVEF improvement ฀ 10% (aHR 0.60 [0.32; 1.14], P = 0.118). However, diabetes was
associated with decreased reverse remodelling with respect to a reduction of left ventricular end-systolic
volume ฀ 15% (aHR 0.45 [0.21; 0.97], P = 0.043). In patients with ischaemic cardiomyopathy, survival
rates were not significantly different between diabetic and non-diabetic patients (HR 1.28 [0.83-1.97], P
= 0.101), whereas in patients with non-ischaemic cardiomyopathy, diabetic patients had a higher risk of
reaching the composite endpoint (HR 1.65 [1.06-2.58], P = 0.027). The latter effect was dependent on
other risk factors (aHR 1.47 [0.83-2.61], P = 0.451). The risk of insulin-dependent patients was not sig-
nificantly higher than in patients under oral antidiabetic drugs (HR 1.55 [95% CI 0.92-2.61], P = 0.102).
CONCLUSIONS Long-term follow-up revealed diabetes mellitus as independent risk factor for all-cause
mortality, heart transplantation, or VAD in heart failure patients undergoing CRT. The detrimental
effect of diabetes appeared to weigh heavier in patients with non-ischaemic compared with ischaemic
cardiomyopathy.
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Abstract
Aims Cardiac resynchronization therapy (CRT) has become an important therapy in patients with heart failure with reduced
left ventricular ejection fraction (LVEF). The effect of diabetes on long-term outcome in these patients is controversial. We
assessed the effect of diabetes on long-term outcome in CRT patients and investigated the role of diabetes in ischaemic
and non-ischaemic cardiomyopathy.
Methods and results All patients undergoing CRT implantation at our institution between November 2000 and January 2015
were enrolled. The study endpoints were (i) a composite of ventricular assist device (VAD) implantation, heart transplantation,
or all-cause mortality; and (ii) reverse remodelling (improvement of LVEF ≥ 10% or reduction of left ventricular end-systolic
volume ≥ 15%). Median follow-up of the 418 patients (age 64.6 ± 11.6 years, 22.5% female, 25.1% diabetes) was 4.8 years
[inter-quartile range: 2.8;7.4]. Diabetic patients had an increased risk to reach the composite endpoint [adjusted hazard ratio
(aHR) 1.48 [95% CI 1.12–2.16], P = 0.041]. Other factors associated with an increased risk to reach the composite endpoint
were a lower body mass index or baseline LVEF (aHR 0.95 [0.91; 0.98] and 0.97 [0.95; 0.99], P < 0.01 each), and a higher
New York Heart Association functional class or creatinine level (aHR 2.14 [1.38; 3.30] and 1.04 [1.01; 1.05], P < 0.05 each).
Early response to CRT, defined as LVEF improvement ≥ 10%, was associated with a lower risk to reach the composite endpoint
(aHR 0.60 [0.40; 0.89], P = 0.011). Reverse remodelling did not differ between diabetic and non-diabetic patients with respect
to LVEF improvement ≥ 10% (aHR 0.60 [0.32; 1.14], P = 0.118). However, diabetes was associated with decreased reverse re-
modelling with respect to a reduction of left ventricular end-systolic volume ≥ 15% (aHR 0.45 [0.21; 0.97], P = 0.043). In pa-
tients with ischaemic cardiomyopathy, survival rates were not significantly different between diabetic and non-diabetic
patients (HR 1.28 [0.83–1.97], P = 0.101), whereas in patients with non-ischaemic cardiomyopathy, diabetic patients had a
higher risk of reaching the composite endpoint (HR 1.65 [1.06–2.58], P = 0.027). The latter effect was dependent on other risk
factors (aHR 1.47 [0.83–2.61], P = 0.451). The risk of insulin-dependent patients was not significantly higher than in patients
under oral antidiabetic drugs (HR 1.55 [95% CI 0.92–2.61], P = 0.102).
Conclusions Long-term follow-up revealed diabetes mellitus as independent risk factor for all-cause mortality, heart trans-
plantation, or VAD in heart failure patients undergoing CRT. The detrimental effect of diabetes appeared to weigh heavier
in patients with non-ischaemic compared with ischaemic cardiomyopathy.
Keywords Cardiac resynchronization therapy; Diabetes mellitus; All-cause mortality; Ischaemic cardiomyopathy; Non-ischaemic
cardiomyopathy
Received: 6 January 2020; Revised: 4 May 2020; Accepted: 16 June 2020
*Correspondence to: Stephan H. Winnik, Department of Cardiology, University Heart Center Zurich, Raemistr. 100, 8091 Zurich, Switzerland. Tel.: +41 44 255 47 82.
Email: stephan.winnik@usz.ch
ORIG INAL RESEARCH ART ICLE
© 2020 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any me-
dium, provided the original work is properly cited and is not used for commercial purposes.
ESC HEART FAILURE
ESC Heart Failure 2020; 7: 2773–2783
Published online 11 July 2020 in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/ehf2.12876
Introduction
The beneficial effects of cardiac resynchronization therapy
(CRT) in selected patients with heart failure with reduced
ejection fraction have been well established.1–3 However, a
relevant proportion of patients do not derive the expected
benefit from CRT. Whereas this may partially be due to a lack
of uptitration of medical therapy,4 a suboptimal position of
the coronary sinus lead or undeliberated device pro
gramming,5 patient selection remains a key issue.6 Therefore,
thorough investigation of all available data is warranted to
identify potential predictors of CRT response in order to fur-
ther ameliorate outcome in daily clinical practice.
Diabetes mellitus (DM) is a strong cardiovascular risk factor
of increasing significance with a growing prevalence among
elderly patients owing to demographic changes worldwide,
and it is associated with increased mortality in patients with
heart failure.7–10 However, the effect of DM on outcome, es-
pecially long-term outcome, in patients receiving CRT remains
controversial. While some cohort studies have demonstrated
a less favourable outcome of CRT in diabetic compared with
non-diabetic patients, other cohort studies as well as post
hoc analyses from the MADIT-CRT, COMPANION, and
CARE-HF did not show a significantly worse outcome in dia-
betic patients.11–20 Average duration of follow-up, however,
ranged between 12 and 34 months across these studies.
It was therefore our aim to investigate the long-term effect
of DM on survival and left ventricular (LV) reverse remodelling
in a real-world setting over a median follow-up of 4.8 years.
Methods
Study population
All patients undergoing CRT implantation at the University
Heart Center Zurich between November 2000 and January
2015, who provided informed consent, were consecutively
enrolled. The study was approved by the local ethics commit-
tee (KEK-ZH-NR: 2011-0304). As reported previously, clinical
and echocardiographic follow-up information was gathered
by chart review for those patients under follow-up at our in-
stitution and by telephone interview for patients with exter-
nal follow-up.21 This previous publication also provides
detailed information of the implantation procedure and
post-operative course.
Endpoints
The endpoints were cardiac survival [defined as the absence
of all-cause mortality, implantation of a ventricular assist
device (VAD), or heart transplantation], and LV reverse
remodelling as determined by echocardiography at
long-term follow-up. Two different parameters were utilized
to estimate reverse remodelling: improvement of LV ejection
fraction (LVEF) by ≥10% or reduction of LV end-systolic vol-
ume index (LVESVI) by ≥15% compared with baseline. Utiliza-
tion of these particular cut-off values has been demonstrated
to be predictive of survival in this cohort.21 Long-term echo-
cardiographic follow-up occurred at 3.9 [2.3; 5.9] years after
CRT implantation.
Statistical analysis
Categorical variables are expressed as frequencies and per-
centages. Numerical Variables are expressed as
mean ± standard deviation or median [inter-quartile range
(IQR)]. Groups were compared using Student’s t-test or
Mann–Whitney U-test for continuous variables, as appropri-
ate, and using contingency χ2 tests for dichotomous vari-
ables. Distribution of continuous variables was assessed
using the Kolmogorov–Smirnov test. Survival curves for
time-to-event analyses were constructed using Kaplan–Meier
estimates based on all available data; comparisons of cumula-
tive events were performed using log rank tests. Multivari-
able analyses were performed utilizing Cox proportional
hazard regression analysis for the survival endpoint and logis-
tic regression analysis for the dichotomous LV remodelling
endpoints. To correct for confounding variables, we included
sex, age, body mass index (BMI), ischaemic cardiomyopathy
(ICM) vs. non-ICM, baseline LVEF, New York Heart Association
(NYHA) class III/IV vs. I/II, baseline creatinine, and N-terminal
pro-brain natriuretic peptide (NT-proBNP) into a model with
DM. In addition, we included the initial response to CRT (de-
fined as LVEF improvement ≥ 10% at first follow-up echocar-
diography) as a time-dependent covariate in the Cox
regression analysis. This approach was also performed sepa-
rately for the subgroups of ICM and non-ICM patients and
in diabetic patients only, in order to compare
insulin-dependent DM (IDDM) and non-insulin-dependent
DM (non-IDDM). All statistical tests were two-sided, and sta-
tistical significance was accepted for P < 0.05. Analyses were
carried out using SPSS software (version 24, IBM).
Results
Study population and baseline characteristics
We investigated 418 patients undergoing CRT implantation
between November 2000 and January 2015 at our institution.
Among these, DM was present in 105 individuals (25.1%),
which was insulin dependent in about a third of cases
(n = 38, 36.2% of diabetic patients, Table 1). While the prev-
alence of female patients did not differ significantly between
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diabetic and non-diabetic patients, diabetic patients were sig-
nificantly older and had a higher BMI (Table 1). Arterial hy-
pertension (64.8% vs. 49.2%, P = 0.006) and relevant kidney
injury as defined by an estimated glomerular filtration rate
(Cockroft–Gault) < 60 mL/min were more prevalent in dia-
betic patients compared with non-diabetic patients (57.1%
vs. 41.2%, P = 0.006). We observed a non-significant differ-
ence in the prevalence of ICM (44.8% vs. 40.9%, P = 0.487).
Average baseline LVEF was found to be slightly but signifi-
cantly lower in diabetic compared with non-diabetic patients
(25.0 ± 7.3 vs. 27.1 ± 8.5%, P = 0.023), while there was no sta-
tistically significant difference in the remaining echocardio-
graphic parameters, including LV volumes or right
ventricular systolic function (Table 1). Importantly, significant
differences neither in QRS width nor in baseline NT-proBNP
levels were observed. The majority of patients was in sinus
rhythm as determined by 12-lead electrocardiogram (ECG)
at the time of CRT implantation in both groups (69.5% vs.
70.5%, P = 0.957). Atrial fibrillation was diagnosed on the
pre-implantation ECG in 11% of patients. Further information
Table 1 Demographics and baseline parameters
All patients Non-diabetic patients All diabetic patients P-value
Demographics
Number of patients 418 313 (74.9%) 105 (25.1%)
Female sex 94 (22.5%) 69 (22.0%) 25 (23.8%) 0.708
Age (years) 64.6 ± 11.6 63.6 ± 12.3 67.3 ± 8.8 0.005
BMI (kg/m
2
) 27.1 ± 5.2 26.7 ± 5.1 28.2 ± 5.4 0.009
Cardiovascular risk factors, co-morbidities
Leading cardiomyopathy
Ischaemic 175 (41.9%) 128 (40.9%) 47 (44.8%) 0.487
Non-ischaemic 243 (58.1%) 185 (59.1%) 58 (55.2%) —
NYHA class 29/108/250/27 24/88/181/17 5/20/69/10 0.097
Arterial hypertension 222 (53.1%) 154 (49.2%) 68 (64.8%) 0.006
Hypercholesterinaemia 188 (45.0%) 132 (42.9%) 56 (53.3%) 0.063
Peripheral artery disease 39 (9.3%) 27 (8.6%) 12 (11.4%) 0.393
History of stroke 35 (8.4%) 27 (8.6%) 8 (7.6%) 0.766
COPD 37 (8.9%) 24 (7.7%) 13 (12.4%) 0.141
Current smoker 93 (22.5%) 72 (23.1%) 21 (20.6%) 0.601
Echocardiographic parameters
LVEF (%) 26.6 ± 8.3 27.1 ± 8.5 25.0 ± 7.3 0.023
LVFS (%) 16.7 ± 8.1 17.1 ± 8.4 15.2 ± 6.9 0.053
LVESVI (mL/m
2
) 82.3 ± 34.6 81.4 ± 35.7 83.8 ± 30.9 0.887
LVEDVI (mL/m
2
) 109.7 ± 38.3 110.5 ± 39.6 107.2 ± 34.4 0.498
RV FAC (%) 38.5 ± 13.8 39.1 ± 14.1 36.7 ± 13 0.294
Electrocardiographic parameters
Heart rate 73.0 ± 14.5 73.1 ± 14.7 72.8 ± 14.1 0.864
QRS width (ms) 156.9 ± 35.1 158.1 ± 34.8 153.1 ± 36.2 0.215
Rhythm on pre-implantation ECG
Sinus rhythm 293 (70.3%) 220 (70.5%) 73 (69.5%) 0.957
Atrial fibrillation 46 (11.0%) 35 (11.2%) 11 (10.5%) -
Paced rhythm 78 (18.7%) 57 (18.2%) 21 (20.0%) -
Laboratory parameters
Creatinine (μmol/L) 124.9 ± 65.6 121.5 ± 63.6 135.5 ± 70.6 0.066
eGFR (mL/min) Cockroft–Gault 68.1 ± 33.3 70.0 ± 34.7 62.4 ± 28.2 0.051
eGFR < 60 mL/min 180 (45.1%) 124 (41.2%) 56 (57.1%) 0.006
NT-proBNP (ng/L) 4490.0 ± 7846.9 4620.7 ± 8365.9 4087.1 ± 6003.3 0.598
Baseline medication
Aspirin 193 (46.3%) 131 (41.9%) 62 (59.6%) 0.002
ACE inhibitor/AR blocker 379 (90.7%) 286 (91.4%) 93 (89.4%) 0.549
Beta-blocker 335 (80.3%) 248 (79.2%) 87 (83.7%) 0.326
Spironolactone 216 (51.9%) 152 (48.7%) 64 (61.5%) 0.023
Loop diuretics 313 (76.7%) 223 (72.9%) 90 (88.2%) 0.001
Thiazide diuretics 73 (18.0%) 55 (18.2%) 18 (17.8%) 0.215
Oral anticoagulation 200 (48.0%) 160 (51.1%) 40 (38.5%) 0.025
Diabetes management
HbA1c—NGSP in % — — 7.0 [6.4;8.0] —
<7% — — 34 (47.9%) —
≥7.0% — — 37 (52.1%) —
Oral antidiabetic therapy — — 59 (57.8%) —
Insulin — — 38 (36.2%) —
ACE, angiotensin converting enzyme; AR, angiotensin receptor; BMI, body mass index; COPD, chronic obstructive pulmonary disease;
eGFR, estimated glomerular filtration rate; LVEDVI, left ventricular end-diastolic volume index; LVEF, left ventricular ejection fraction;
LVESVI, left ventricular end-systolic volume index; LVFS, left ventricular fractional shortening; NGSP, National Glycohemoglobin Standard-
ization Program; NYHA, New York Heart Association; RV FAC, right ventricular fractional areal change.
Bold indicates statistically significant findings.
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on echocardiographic and electrocardiographic parameters,
as well as medical therapy, is listed in Table 1. CRT with defi-
brillator (CRT-D) were implanted in 87.2% and 88.6% of
non-diabetic and diabetic patients, respectively (P = 0.717).
Within the diabetic population, the comparison of IDDM to
non-IDDM patients did not reveal any significant differences
in any of the demographic or baseline clinical parameters (Ta-
ble S1). Approximately half of all diabetic patients had an
HbA1c level below 7.0%, with a median HbA1c level of 7.0%
[IQR: 6.4%; 8.0%] in the overall diabetic population. Compar-
ison of HbA1c levels in IDDM and non-IDDM subgroups, dem-
onstrated slightly but statistically significantly higher HbA1c
levels in insulin-dependent compared with non-insulin-
dependent diabetics (7.2% [6.6%; 8.7%] vs. 6.8% [6.3%; 7.6]).
Long-term clinical follow-up—diabetic vs.
non-diabetic patients
Patients were followed up for the composite endpoint of
all-cause mortality, heart transplantation, or VAD implanta-
tion for a median time of 4.8 [2.8; 7.4] years. This composite
endpoint was reached in 58 of 105 (55.2%) diabetic patients
and in 130 of 313 (41.5%) non-diabetic patients (HR 1.50
[1.10; 2.04], P = 0.011) (Figure 1A and Table 2). Kaplan–Meier
estimates for freedom from the composite endpoint at
5 years were 50% vs. 63% (DM vs. non-DM, P = 0.011).
Among others, further, factors associated with worse out-
come for the composite endpoint in univariable analysis were
age (HR 1.02 [1.01; 1.04] per year), reduction of LVEF (HR
1.02 [1.01; 1.04] per % LVEF reduction), NYHA class III/IV vs.
I/II (HR 1.96 [1.37; 2.80]), ICM (HR 1.64 [1.23; 2.18]), baseline
creatinine (HR 1.06[1.05; 1.08] per 10 μmol/L increase), and
NT-proBNP (HR 1.03 [1.02–1.04] per 1000 ng/L increase). Im-
portantly, initial CRT response defined by LVEF
improvement ≥ 10% at first follow-up echocardiography (7.0
[3.9; 9.7] months after implantation) was associated with a
significant hazard ratio (HR 0.46 [0.33–0.64]). After multivar-
iable correction for these and further clinically relevant vari-
ables (Table 3), including initial CRT response as a
time-dependent covariate, adjusted HR for diabetic over
non-diabetic patients remained statistically significant with a
hazard ratio of 1.48 [1.02; 2.16] for the composite endpoint
(Tables 2 and 3).
Comparison of LVEF in diabetic and non-diabetic patients
at their last follow-up echocardiography after a median of
3.9 [2.3; 5.9] years after CRT implantation did not show a sig-
nificant difference, neither in absolute numbers nor with re-
spect to the relative change compared with the
pre-implantation LVEF (Figure 1B): average LVEF after CRT
implantation was 33.6% ± 12.8% vs. 36.0% ± 14.4%
(P = 0.058), and average change in LVEF was +8.4% ± 14.0%
vs. +9.1% ± 14.3% in diabetic and non-diabetic patients,
respectively. The adjusted HR for reaching an LVEF
improvement ≥ 10% was 0.60 [0.32; 1.14] in diabetic vs.
non-diabetic patients (Table 2 and Figure 1C). Similarly, im-
provements in end-systolic volumes on long-term follow-up
were not significantly different between diabetic and
non-diabetic patients (average change: 13.5 ± 31.3 vs.
12.9 ± 40.6 mL/m2 in diabetic vs. non-diabetic patients,
Figure 1D). However, when utilizing a cut-off at ≥15% LVESVI
reduction, diabetics demonstrated a significantly reduced
prevalence of LV reverse remodelling than did non-diabetics
(adjusted HR 0.45 [0.21; 0.97], Table 2 and Figure 1F).
Diabetes mellitus in ischaemic vs. non-ischaemic
cardiomyopathy
Because diabetes is a strong risk factor for ICM, we assessed
the effect of diabetes in CRT patients stratified for ICM vs.
non-ICM. Comparison of diabetic and non-diabetic patients
within the subgroup of patients with ICM did not reveal a sig-
nificant difference in the composite endpoint (Figure 2A, Ta-
ble 4). In patients with non-ICM, diabetic patients did worse
than did non-diabetic patients on unadjusted analysis (HR
1.65 [1.06; 2.58], P = 0.027, Figure 2D, Table 4). Diabetes
was not associated with alterations in LV reverse remodelling
as assessed by changes in LVEF or LVESVI in either subgroup
(Figure 2B–F).
Effect of insulin dependency on outcomes in
diabetic cardiac resynchronization therapy
patients
To further dissect the role of diabetes in CRT patients, we
compared the outcome in IDDM vs. non-IDDM diabetic CRT
patients. We found a trend towards a reduced freedom from
the composite endpoint in IDDM vs. non-IDDM patients (ad-
justed HR 1.61 [0.80; 3.26], P = 0.185, Table 5, Figure 3A). In-
terestingly, survival curves began to separate only 3 years
after CRT implantation. A trend towards an improved LV re-
verse remodelling in patients with vs. without IDDM did not
reach statistical significance (Figure 3B and C).
Discussion
Over a median follow-up of 4.8 years after CRT implantation,
diabetic patients had an increased risk to reach the compos-
ite endpoint of all-cause mortality, heart transplantation, or
VAD implantation in this single-centre real-world cohort. This
effect was also evident in the subgroup of patients with
non-ICM in univariable analysis, but not in patients with
ICM; this differential effect may indicate that the increased
mortality risk associated with DM is mediated by pathophys-
iological mechanisms distinct from increased atherosclerosis
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Figure 1 Outcome data stratified for diabetes mellitus (DM) vs. no DM: (A) Kaplan–Meier survival curves for the composite endpoint of all-cause death,
heart transplantation, or ventricular assist device (VAD) implantation. (B) Box plots showing inter-quartile ranges for left ventricular ejection fraction
(LVEF) pre-CRT and post-CRT implantation, stratified for DM vs. no DM. Whiskers indicate minima and maxima. (C, D) Stacked bar graph showing cat-
egorized left ventricular remodelling in the form of absolute LVEF improvement and relative LVESVI improvement, respectively.
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and macrovascular disease. Yet the worse prognosis of pa-
tients with ICM compared with non-ICM may also outweigh
the additional risk conferred by DM among patients with
ICM. The increased mortality risk associated with DM was
not accompanied by a strong signal for impaired LV reverse
remodelling, which has been considered a main mechanism
underlying improved survival after CRT.22,23 While we did
not observe an association between diabetes and LV reverse
remodelling defined by an improvement in LVEF ≥ 10% com-
pared with baseline, diabetes was associated with an im-
paired CRT response if defined as a reduction of LVESVI by
≥15%. This difference may be due to LVESVI being the more
sensitive parameter compared with LVEF. However, this re-
sult needs to be interpreted with great care owing to larger
number of missing data for this variable (data completeness
414/418 for LVEF and 263/418 for LVESVI).
The discrepancy of survival and LV remodelling may hint
towards a role for other mechanisms underlying improved
survival upon CRT than mere mechanical and hemodynamic
changes.24–26 Besides a predisposition to ischaemic injury,
that is, coronary artery disease, further DM-associated mech-
anisms have been described to result in myocardial damage
(reviewed by Bugger and Abel27). These mechanisms include
altered myocardial metabolism and mitochondrial dysfunc-
tion, altered cell homeostatic processes regulating apoptosis,
and autophagy along with changes in gene regulation. In
combination, these molecular alterations result in impaired
cardiac contractility and compliance as well as
electroanatomical function, all of which are prerequisites for
the beneficial effects of CRT.9,12,28,29 Determining the causes
of our findings in this diabetic subpopulation, including the
prevalence of atrial and ventricular arrhythmic events, which
have been demonstrated to be associated with heart failure
outcome, will be subject for further research.30 Conse-
quently, worse prognosis with worse glycaemic control in
DM should be presumed, and there was an according trend
with increased mortality risk in patients with IDDM vs.
non-IDDM without statistical significance, which may be re-
lated to insufficient statistical power.
Our data add to previous cohort studies, further shifting
the balance of existing evidence towards a less favourable
long-term outcome of CRT in diabetic compared with
non-diabetic patients.11–14 This appears intuitive considering
the role of DM as a strong cardiovascular risk factor and
Table 3 Univariable and multivariable analyses for reaching the endpoint in the study population
Univariate Multivariate
HR 95% CI P-value aHR 95% CI P-value
Diabetes 1.50 [1.10; 2.04] 0.011 1.48 [1.02; 2.16] 0.041
Male sex 1.46 [1.00; 2.14] 0.051 1.61 [0.97; 2.69] 0.070
Age 1.02 [1.01; 1.04] 0.005 1.00 [0.98; 1.02] 0.829
BMI 0.98 [0.95; 1.00] 0.076 0.95 [0.91; 0.98] 0.003
LVEF (%) 0.98 [0.96; 1.00] 0.012 0.97 [0.95; 0.99] 0.008
NYHA ≥ III 1.96 [1.37; 2.80] <0.001 2.14 [1.38; 3.30] 0.001
Ischaemic cardiomyopathy 1.64 [1.23; 2.18] <0.001 1.62 [1.14; 2.31] 0.008
Creatinine (10 μmol/L) 1.06 [1.05; 1.08] <0.001 1.04 [1.01; 1.08] 0.012
NT-proBNP (1000 ng/L) 1.03 [1.02; 1.04] <0.001 1.01 [0.99, 1.04] 0.260
Initial CRT response 0.46 [0.33; 0.64] <0.001 0.60 [0.40; 0.89] 0.011
aHR, adjusted hazard ratio; CI, confidence interval; BMI, body mass index; LVEF, left ventricular ejection fraction; NYHA, New York Heart
Association class.
Endpoint was defined as a composite of all-cause mortality, heart transplantation, or ventricular assist device implantation. Initial CRT re-
sponse was defined as an improvement in left ventricular ejection fraction ≥ 10% compared with baseline at initial follow-up echocardi-
ography (7.0 [3.9; 9.7]) months after implantation. All variables were included in the multivariate analysis, including CRT response as a
time-dependent covariate.
Bold indicates statistically significant findings.
Table 2 Number of diabetic and non-diabetic patients reaching endpoints
All patients Non-diabetic patients Diabetic patients
Statistical comparison
aHR 95% CI P-value
Composite endpoint of death,
transplantation, or VAD
45.0% (n = 188) 41.5% (n = 130) 55.2% (n = 58) 1.48 [1.02; 2.16] 0.041
LV reverse remodelling
By ≥10% LVEF improvement 47.4% (n = 198) 48.9% (n = 153) 44.9% (n = 45) 0.60 [0.32; 1.14] 0.118
By ≥15% LVESVI reduction 51.5% (n = 123) 55.7% (n = 102) 37.5% (n = 21) 0.45 [0.21; 0.97] 0.043
The endpoint was defined as a composite of all-cause mortality, heart transplantation, or ventricular assist device (VAD) implantation. Left
ventricular (LV) reverse remodelling was defined as an improvement in LV ejection fraction (LVEF) ≥ 10% or reduction of LV end-systolic
volume index (LVESVI) by ≥15% compared with baseline.
aHR, adjusted hazard ratio; CI, confidence interval.
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independent predictor of mortality in heart failure in general.
However, post hoc analyses of the major randomized con-
trolled CRT trials, including COMPANION, CARE-HF, and
MADIT-CRT, have not identified any interaction between dia-
betes and their primary outcome.16–20 More importantly,
compared with the majority of previous studies, we provide
a markedly longer follow-up.11–14,16,19,20,31 This appears to
be of particular relevance because survival curves of diabetic
and non-diabetic patients begin to separate no earlier than
2 years after CRT implantation. Therefore, follow-up time of
earlier studies may have been too short to identify an effect.
Of note, whereas our data indicate an inferior outcome of
CRT associated with DM, the subgroup of diabetic patients
in Echo-CRT, which investigated the effect of CRT in heart fail-
ure patients with narrow QRS complex, derived less harm
from CRT compared with non-diabetic patients.32 This may
signal a reduced therapeutic effect of CRT in diabetic pa-
tients. Importantly, none of the randomized controlled CRT
trials was specifically designed and therefore potentially not
powered to assess a differential role of DM in CRT. Our
cohort represents a cohort of consecutively enrolled patients
in a real-world setting. While the baseline characteristics of
our study are very similar to those of the major clinical trials,
patient enrolment was not limited by specific inclusion or ex-
clusion criteria of a study protocol.
Our data furthermore corroborate previous findings, iden-
tifying ICM as an independent predictor for all-cause mortal-
ity in heart failure patients with CRT.33–35 Yet data on the role
of DM in patients with ICM compared with non-ICM are
scarce. Intriguingly, the detrimental effect of DM on
long-term outcome after CRT appeared to weigh heavier in
patients with non-ICM compared with those with ICM. Failure
to reach significance after adjusting for other risk factors may
be attributed to a lack of statistical power in this subgroup of
our cohort. However, our findings may also indicate that the
additional risk seen with DM in non-ICM disappears in ICM
owing to the overall higher risk of mortality in this patient
population. A similar signal was seen in a substudy of Echo-
CRT, where diabetics with non-ICM derived the least harm
from CRT.32
Figure 2 Outcome data stratified for diabetes mellitus (DM) vs. no DM in the subgroups of ischaemic and non-ischaemic cardiomyopathy. (A) Kaplan–
Meier survival curves in the subgroup of ischaemic cardiomyopathy for the composite endpoint of all-cause mortality, heart transplantation, or ven-
tricular assist device (VAD) implantation. (B, C) Stacked bar graph showing categorized left ventricular remodelling in the form of absolute left ventric-
ular ejection fraction (LVEF) and relative LV end-systolic volume index (LVESVI) improvement for the subgroup of ischaemic cardiomyopathy,
respectively. (D–F) Same as (A–C) for the subgroup of non-ischaemic cardiomyopathy.
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The limited available data on the role of insulin therapy
among diabetic CRT patients are controversial at best. While
two post hoc analyses of MADIT-CRT observed that
CRT-mediated risk reduction was confined to
insulin-dependent diabetics,18,20 insulin use was found to
confer additional risk in two well-conducted cohort
studies.13,36 We did not identify a clear signal differentiating
the role of IDDM vs. non-IDDM in our cohort. A trend to-
wards a reduced mortality risk in patients with non-IDDM
compared with patients with IDDM did not reach significance.
Limitations
The present study is an observational, single-centre, retro-
spective cohort study. Endpoints were defined post hoc but
correspond to those used in large prospective outcome trials.
The number of patients in this cohort is limited, as this is a
single-centre study. Consecutive enrolment until January
2015 leads to a certain variance of follow-up times. Impor-
tantly, however, follow-up is very complete, with median
follow-up of 4.8 years, longer than in most previous studies.
Table 4 Univariable and multivariable analyses for reaching the endpoint in the study population—stratified by type of underlying
cardiomyopathy
Univariate Multivariate
HR 95% CI P-value aHR 95% CI P-value
A. Ischaemic cardiomyopathy
Diabetes 1.28 [0.83; 1.97] 0.261 1.55 [0.92; 2.62] 0.101
Male sex 0.70 [0.40; 1.22] 0.211 0.63 [0.30; 1.33] 0.229
Age 1.02 [0.99; 1.22] 0.179 1.01 [0.98; 1.04] 0.763
BMI 0.99 [0.96; 1.03] 0.803 0.99 [0.94; 1.05] 0.802
LVEF (%) 0.97 [0.94; 0.99] 0.013 0.97 [0.93; 1.00] 0.041
NYHA ≥ III 2.15 [1.26; 3.68] 0.005 2.12 [1.13; 3.97] 0.020
Creatinine (10 μmol/L) 1.07 [1.04; 1.09] <0.001 1.03 [0.97; 1.08] 0.345
NT-proBNP (1000 ng/L) 1.07 [1.04; 1.10] <0.001 1.05 [0.99; 1.12] 0.090
Initial CRT response 0.64 [0.41; 1.01] 0.053 0.70 [0.39; 1.26] 0.232
B. Non-ischaemic cardiomyopathy
Diabetes 1.65 [1.06; 2.58] 0.027 1.47 [0.83; 2.61] 0.451
Male sex 1.90 [1.12; 3.21] 0.017 3.12 [1.53; 6.38] 0.002
Age 1.02 [1.00; 1.04] 0.076 0.99 [0.97; 1.01] 0.442
BMI 0.95 [0.91; 0.99] 0.016 0.89 [0.84; 0.94] <0.001
LVEF (%) 0.98 [0.96; 1.01] 0.214 0.97 [0.94; 1.01] 0.124
NYHA ≥ III 1.69 [1.04; 2.73] 0.033 2.44 [1.30; 4.60] 0.006
Creatinine (10 μmol/L) 1.06 [1.04; 1.08] <0.001 1.05 [0.99; 1.09] 0.084
NT-proBNP (1000 ng/L) 1.03 [1.02; 1.05] <0.001 1.02 [0.99; 1.05] 0.259
Initial CRT response 0.37 [0.23; 0.60] <0.001 0.45 [0.25; 0.81] 0.008
aHR, adjusted hazard ratio; BMI, body mass index; CI, confidence interval; HR, hazard ratio; LVEF, left ventricular ejection fraction; NYHA,
New York Heart Association class.
Endpoint was a composite of all-cause death, heart transplantation, or ventricular assist device implantation. Initial CRT response was de-
fined as an improvement in left ventricular ejection fraction ≥ 10% compared with baseline at initial follow-up echocardiography (7.0 [3.9;
9.7] months after implantation. All variables were included in the multivariate analysis, including CRT response as a time-dependent
covariate.
Bold indicates statistically significant findings.
Table 5 Univariable and multivariable analyses for reaching the endpoint in diabetic patients
Univariate Multivariate
HR 95% CI P-value aHR 95% CI P-value
IDDM vs. non-IDDM 1.55 [0.92; 2.61] 0.102 1.61 [0.80; 3.26] 0.185
Male sex 1.27 [0.66; 2.46] 0.478 2.36 [0.63; 8.84] 0.204
Age 1.00 [0.98; 1.00] 0.795 1.06 [1.01; 1.12] 0.016
BMI 1.03 [0.98; 1.08] 0.208 1.08 [0.99; 1.17] 0.071
LVEF (%) 0.93 [0.89; 0.96] <0.001 0.86 [0.80; 0.92] <0.001
NYHA ≥ III 1.76 [0.86; 3.58] 0.122 6.45 [1.97; 21.06] 0.002
Ischaemic cardiomyopathy 1.34 [0.80; 2.24] 0.272 1.73 [0.85; 3.54] 0.133
Creatinine (10 μmol/L) 1.06 [1.04; 1.09] <0.001 0.99 [0.88; 1.11] 0.838
NT-proBNP (1000 ng/L) 1.05 [1.02; 1.08] 0.002 1.09 [1.00; 1.19] 0.057
Initial CRT response 0.90 [0.54; 1.61] 0.795 1.22 [0.56; 2.65] 0.626
aHR, adjusted hazard; HR, hazard ratio.
Endpoint was a composite of all-cause death, heart transplantation, or ventricular assist device implantation. Initial CRT response was de-
fined as an improvement in left ventricular ejection fraction ≥ 10% compared with baseline at initial follow-up echocardiography (7.0 [3.9;
9.7] months after implantation. All variables were included in the multivariate analysis, including CRT response as a time-dependent
covariate.
Bold indicates statistically significant findings.
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Nevertheless, we cannot exclude a type I error while compar-
ing the characteristics of patients with and without diabetes.
Moreover, inclusion at a single centre may introduce a selec-
tion and/or referral bias. Of note, baseline characteristics of
our cohort are very similar to those in most large trials, sug-
gesting that, even if present, selection and referral bias were
likely negligible. The baseline characteristics of the diabetic
group are different from those of the non-diabetic group. Di-
abetic patients are older and had more frequently arterial hy-
pertension, chronic coronary artery disease, and a lower
LVEF. Propensity score matching in this study would have
been difficult as (i) the relevant variables to calculate the pro-
pensity score for the development of diabetes as exposure
variable are not available in our (and most other published)
study(s) and (ii) matching might substantially reduce the sam-
ple size, even if these variables were available. Therefore, we
chose a non-matched cohort approach, adjusting the analysis
for the known and available confounders. Importantly, creat-
inine, along with age and BMI, were accounted for in the mul-
tivariable models.
Recent advances in antidiabetic medical therapy with
GLP-1 agonists and SGLT2 inhibitors, which may affect out-
come of CRT in diabetic patients, are not considered in this
manuscript because the vast majority of CRT implantations
was performed prior to marketing of these drugs.37
Quadripolar coronary sinus leads were utilized in the majority
of patients as soon as marketed. Importantly, multipoint pac-
ing was not routinely applied in our patients. Therefore, the
effect of multipoint pacing cannot be assessed in this cohort.
The effect of quadripolar compared with bipolar leads was
not the focus of the current study.38 While focusing on sur-
vival as a hard endpoint, follow-up of patients outside our
centre did not allow us to collect unambiguous data on hos-
pitalizations for worsening heart failure in this cohort, an-
other widely used endpoint. The information provided on
heart rhythm at baseline represents the rhythm during
pre-implantation 12-lead ECG and does not allow differentia-
tion between permanent, persistent, and paroxysmal atrial fi-
brillation. Finally, as in every retrospective registry, residual
confounding cannot be excluded.
Conclusions
Diabetes confers an increased mortality risk in heart failure
patients after CRT implantation. This risk appears to weigh
heavier in patients with non-ICM and is not reflected by an
impaired reverse remodelling. Intriguingly, survival curves of
diabetic and non-diabetic patients begin to separate no ear-
lier than 2 years after CRT implantation, which is why the
follow-up of earlier studies, including the sub-studies of the
major randomized trials, may have been too short to detect
this signal.
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